The companies also have an expanded three-year software agreement that will increase access for Novartis to Schrödinger’s ...

Pharmaceuticals Canada said it is “extremely disappointed” that negotiations for Pluvicto, a treatment for patients ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of ...

Midtown-based drug discovery company Schrodinger has entered a deal to advance multiple projects with pharmaceutical giant ...

Spherix has been tracking the C3G market for over four years in both the U.S. and Europe. The studies have provided meaningful insights into physician perceptions of unmet needs and expectations for ...

Schrodinger (SDGR) today announced a research collaboration and license agreement with Novartis (NVS) to advance multiple ...

Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis is paying $150 million for a closer look at Schrödinger’s catalog of programs. The Big Pharma will work with Schrödinger to advance some of the computing-enabled R&D shop’s discovery programs ...

Schrodinger, Inc. (NASDAQ:SDGR) shares are trading higher on Tuesday. The company disclosed a research collaboration and ...

When I (Kody) last covered Novartis with a buy rating in May, I liked its continuity as a business. The company's product portfolio and pipeline were also impressive. Novartis' balance sheet was ...

Physics-based US software specialist Schrödinger’s shares leapt nearly 14% to $22.25 on the back of news that it has entered ...

Qatar is to adopt the Cardio4cities approach – a data-driven cardiovascular population health initiative – and become the ...